http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The effect of LAMA and LABA on lung function in bronchiectasis patients
( Suyeon Lee ),( Yeon Mok Oh ),( Sei Won Lee ),( Jae Seung Lee ) 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.-
Background: Bronchiectasis is a chronic lung disease characterized by coughing, sputum, and repeated bronchial infections with permanent bronchial dilatation. One of the treatment goal for bronchiectasis is maintaining or improving lung function. In practice, long-acting muscarinic antagonist (LAMA) or beta-agonist (LABA) inhaled bronchodilators are often used to treat bronchiectasis, but there is very low evidence to recommend their use. So the aim of this study is to evaluate the effectiveness of LAMA or LABA in bronchiectasis patients by comparing lung function before and after LAMA or LABA treatment. Methods: This study was a retrospective, observational study comparing lung function, before and after LAMA or LABA treatment. We analyzed the data of 230 bronchiectasis patients who were treated with LAMA or LABA for at least one month without any history of asthma or cigarette smoking. We similarly analyzed the data of 97 patients, after excluding those treated with antibiotics, steroids, or mucolytics. We identified the factors relating to the increase in FEV1 values after the treatment of LAMA or LABA with linear regression analysis. Results: Of 230 patients, 32.5% were male, and the median age was 60 years. Mean FEV1 was 53.5% of predicted value. After treatment with LAMA or LABA, we found improvement of FEV1 (P<0.001). The mean change in FEV1 was 5%±8.9% of the predicted value. After excluding the patients treated with antibiotics, steroids or mucolytics, we also found improvement of FEV1 (P<0.001), with a mean change of 5.7%±7.8%. The factors relating to the increase in FEV1 were mMRC dyspnea grade and baseline FEV1 value. The lower the mMRC dyspnea grade, the greater the change of FEV1 (P=0.005); the lower the baseline FEV1 value, the greater the change of FEV1 (P=0.0001). Conclusions: LAMA or LABA treatment might improve lung function in bronchiectasis patients.
( Suyeon Jin ),( Chan Joo Lee ),( Gibbeum Lim ),( Sungha Park ),( Sang-hak Lee ),( Ji Hyung Chung ),( Jaewon Oh ),( Seok-min Kang ) 생화학분자생물학회 2023 BMB Reports Vol.56 No.12
C-reactive protein (CRP) is an inflammatory marker and risk factor for atherosclerosis and cardiovascular diseases. However, the mechanism through which CRP induces myocardial damage remains unclear. This study aimed to determine how CRP damages cardiomyocytes via the change of mitochondrial dynamics and whether survivin, an anti-apoptotic protein, exerts a cardioprotective effect in this process. We treated H9c2 cardiomyocytes with CRP and found increased intracellular ROS production and shortened mitochondrial length. CRP treatment phosphorylated ERK1/2 and promoted increased expression, phosphorylation, and translocation of DRP1, a mitochondrial fission-related protein, from the cytoplasm to the mitochondria. The expression of mitophagy proteins PINK1 and PARK2 was also increased by CRP. YAP, a transcriptional regulator of PINK1 and PARK2, was also increased by CRP. Knockdown of YAP prevented CRP-induced increases in DRP1, PINK1, and PARK2. Furthermore, CRP-induced changes in the expression of DRP1 and increases in YAP, PINK1, and PARK2 were inhibited by ERK1/2 inhibition, suggesting that ERK1/2 signaling is involved in CRP-induced mitochondrial fission. We treated H9c2 cardiomyocytes with a recombinant TAT-survivin protein before CRP treatment, which reduced CRP-induced ROS accumulation and reduced mitochondrial fission. CRP-induced activation of ERK1/2 and increases in the expression and activity of YAP and its downstream mitochondrial proteins were inhibited by TAT-survivin. This study shows that mitochondrial fission occurs during CRPinduced cardiomyocyte damage and that the ERK1/2-YAP axis is involved in this process, and identifies that survivin alters these mechanisms to prevent CRP-induced mitochondrial damage. [BMB Reports 2023; 56(12): 663-668]
Lee, Jihyoun,Kim, Sungwon,Kang, Eunyoung,Park, Suyeon,Kim, Zisun,Lee, Min Hyuk 한국유방암학회 2017 Journal of breast cancer Vol.20 No.2
<P>Lack of awareness, the stigma of carrying a genetic mutation, and economic factors are barriers to acceptance of <I>BRCA</I> genetic testing or appropriate risk management. We aimed to investigate the influence of Angelina Jolie's announcement of her medical experience and also health insurance reimbursement for <I>BRCA</I> gene testing on practice patterns for hereditary breast and ovarian cancer (HBOC). A survey regarding changes in practice patterns for HBOC before and after the announcement was conducted online. The rate of <I>BRCA</I> gene testing was obtained from the National Health Insurance Review and Assessment Service database. From May to August 2016, 70 physicians responded to the survey. Genetic testing recommendations and prophylactic management were increased after the announcement. Risk-reducing salpingo-oophorectomy and contralateral prophylactic mastectomy was significantly increased in <I>BRCA</I> carriers with breast cancer. The <I>BRCA</I> testing rate increased annually. Health insurance and a celebrity announcement were associated with increased genetic testing.</P>